Characterization of Clinical Grade CD19 Chimeric Antigen Receptor T Cells Produced Using Automated CliniMACS Prodigy System

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s175113
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

Frontiers in Immunology
AllergyImmunology
2019English

169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Comprehensive Report of Anti-Cd19 Chimeric Antigen Receptor T-Cells (Car-T) Associated Non Relapse Mortality (Cart-Nrm) From Faers

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Chimeric Antigen Receptor T Cells for the Treatment of Lymphoma

Annals of Lymphoma
2017English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy